Albany, NY (PRWEB) December 25, 2013
Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period.
Browse Full Report With TOC at: http://www.researchmoz.us/global-and-china-monoclonal-antibody-industry-report-2013-2017-report.html
Thanks to robust market demand, approval of new products and new indications as well as launch of monoclonal antibody generic drugs, the global monoclonal antibody market size will ascend by more than 12% in 2013-2017, hitting USD141 billion in 2017.
Driven by enhanced economic level, expanded scope of medical insurance reimbursement, as well as lower prices incurred by intensified competition, Chinese monoclonal antibody market is expected to continue to grow significantly. In 2013-2017, Chinese monoclonal antibody market will grow at 35%, sharing 21.5% of the global monoclonal antibody market in 2017 (9.5% in 2012).
The global monoclonal antibody industry is still dominated by European and American companies, especially, important monoclonal antibody products are mainly produced by Roche (Genentech), Amgen, AbbVie (Abbott), Johnson & Johnson and other companies. In 2012, the global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (AbbVie) and Trastuzumab (Roche) stemmed from the above four companies. The global sales (including the sales of third parties) of these six monoclonal antibody agents totaled USD45 billion, accounting for 57.7% of the global.
Find More Reports from Research in China Publisher at: http://www.researchmoz.us/publisher/research-in-china-67.html
In recent years, China monoclonal antibody industry has been developing fast with the market size CAGR of 44.6% in 2010-2012. More than 100 companies have been involved in monoclonal antibody agents, and 10 ones of them have conducted clinical applications. The Chinese market is dominated by Rituximab, Trastuzumab, Infliximab, Bevacizumab and other imported products, all of which occupied 70-75% market share totally in 2012.
However, by virtue of price and geographical advantages, the competitiveness of Chinese local monoclonal antibody products has been gradually improved, such as the competition between Nimotuzumab and Cetuximab. The market share of Merck's Cetuximab in China shrinks and was excluded from top 200 drugs purchased by Chinese 22 typical urban hospitals in 2012 with the value of RMB130 million (down 16.35% year on year).
Global Bioinformatics Market 2014-2018
Global Bioinformatics market to grow at a CAGR of 26.15 percent over the period 2013-2018. One of the key factors contributing to this market growth is the decreasing cost of genetic sequencing. The Global Bioinformatics market has also been witnessing the increasing outsourcing of bioinformatics services. However, the complexity in using bioinformatics tools could pose a challenge to the growth of this market. The Global Bioinformatics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC region; it also covers the Global Bioinformatics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Browse Full Report with TOC at: http://www.researchmoz.us/global-bioinformatics-market-2014-2018-report.html
China Heparin Industry Report, 2013-2015
Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradually recognized internationally, China has grown into the largest heparin API producing and exporting country around the globe. Nevertheless, due to the stagnant demand in European and American markets in recent two years and the improved standards for heparin export, the export volume and value of heparin APIs in China both presented a decline trend during 2011-2012.
Browse Full Report wtih TOC at: http://www.researchmoz.us/china-heparin-industry-report-2013-2015-report.html
ResearchMoz ( http://www.researchmoz.us/ ) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.
For More Information Kindly Contact:
Toll Free: 866-997-4948
90 State Street, Suite 700
Albany, NY 12207
Read the full story at http://www.prweb.com/releases/2013/12/prweb11446822.htm.
Copyright©2012 Vocus, Inc.
All rights reserved